Alnylam Pharmaceuticals | ALNY - Interest Income



Alnylam Pharmaceuticals reported $27.49M in Interest Income for its fiscal quarter ending in June of 2025.


Interest Income Change Date
Acadia Pharmaceuticals USD 7.24M 658K Jun/2025
Agios Pharmaceuticals USD 14.51M 1.57M Jun/2025
Alnylam Pharmaceuticals USD 27.49M 1.19M Jun/2025
Arrowhead Research USD 9.62M 2.01M Mar/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Incyte 25.14M 2.21M Jun/2025
Ionis Pharmaceuticals -0.66 0.29 Dec/2024
Moderna USD 81M 9M Jun/2025
Regeneron Pharmaceuticals 174.8M 1.3M Jun/2025
Sanofi 76M 77M Jun/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Takeda 73.76B 81.93B Jun/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025
Xencor USD 7.25M 290K Jun/2025